Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Vascular Regeneration (SEMA-VR)
NCT05870462Phase 4Unknown
- Sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Canadian Medical and Surgical Knowledge Translation Research Group. Primary endpoint: Mean frequency of circulating ALDHhiSSClow primitive progenitor cells at 6 months. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05870462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870462.